Skip to content Skip to footer
Subscribe Now
Pharma Tech Conclave 2023
EVENTS

Pharma Tech Conclave 2023

Chitkara University and DeepSynergy presents the Pharma Tech Conclave 2023. The conference will be held on 3rd Mar 2023 from 9:00 am to 5:00 pm IST at the Chitkara College of Pharmacy, Chitkara University, Chandigarh. The global pharmaceutical industry is undergoing transformational changes due to advancements in technological innovations that aim to fundamentally alter how patients…
February 22, 2023

Read more

VIEWPOINTS_Suresh Kannan_2023
VIEWPOINTS

Suresh Kannan, Chief Product Officer at Model N Shares Insights on the Fall 2022 Product Release of the Model N Revenue Cloud

Shots: Suresh Kannan discussed the latest semi-annual update to bring innovative revenue optimization and compliance solution for life sciences and high-tech innovators He elaborated on the Fall 2022 product release, providing customers with tools to improve automation, efficiency, and profitability during economic uncertainty along with streamlined pricing communication The interview gives an understanding of how…
February 16, 2023

Read more

VIEWPOINTS_Whitney Stewart_2023
VIEWPOINTS

Whitney Stewart, Director of Clinical Project Management at Curebase Shares Insights from the Release of a Publication with Digital Therapeutics Alliance

Shots:  Whitney gave a brief on the partnership of Curebase with Digital Therapeutics Alliance to provide fit-for-purpose evidence standard for DTx product regulatory, reimbursement, and clinical acceptance  Whitney also elaborated on the Fit-for-Purpose Evidentiary standards and talked about why  the DTx devices do not fit in the standards for medical devices by quoting some examples …
February 14, 2023

Read more

VIEWPOINTS_Nicolas Paquette-Lamontagne_2023
VIEWPOINTS

Nicolas Paquette-Lamontagne, VP, Medical Affairs at Blueprint Medicines Shares his Views on Clinical Data of Ayvakit for Patients with Systemic Mastocytosis

Shots:  Nicolas discussed about Systemic Mastocytosis as a disease and highlighted its epidemiology & other details. He also spoke about the clinical data of avapritinib presented at the ASH’22 Annual Meeting     Nicolas also shared the key findings from the PATHFINDER and EXPLORER trial evaluating avapritinib and the rationale behind conducting two different trials  This interview…
February 13, 2023

Read more

VIEWPOINTS_Dr. Philip M. Toleikis_2023
VIEWPOINTS

Dr. Philip M. Toleikis, President & CEO at Sernova Shares Insights on the Partnership with Evotec to Develop a ‘Functional Cure’ for Diabetes

Shots:  Dr. Philip shared his views on the collaboration of Sernova with Evotec for iPSC-Based Beta cell replacement therapy to develop and commercialize a ‘Functional Cure’ for diabetes.   He also gave an overview on the benefits of Evotec’s iPSC-based insulin-producing beta cells on the next generation of Sernova’s Cell Pouch System  The interview discusses about how Sernova…
February 7, 2023

Read more

VIEWPOINTS_Toni R. Hofhine_2023
VIEWPOINTS

Toni R. Hofhine, President of ATCOR Medical (CardieX) Shares Insights from Pulse- a New at-home Heart Health Monitor

Shots: Toni spoke about the CONNEQT Pulse the first dual blood pressure monitor with ATCOR’s SphygmoCor technology. The device is used for remote patient monitoring, home health, and clinical trials  She also elaborated about the data used for the pre-marketing submission with FDA. She explained the seven key vascular biomarkers that the device measures and…
February 6, 2023

Read more

VIEWPOINTS_John Gabrielson_2023
VIEWPOINTS

John Gabrielson SVP, Biosimilars & Head of Business of Similis Bio (JSR Life Sciences) Shares Insights on the Partnership with Blau Farmaceutica to Co-Develop Four Biosimilar Programs

Shots:  John spoke about the agreement between Similis Bio (a biosimilar partner and affiliate company of JSR) and Blau Farmaceutica to develop products and license IP for four biosimilar assets targeting indications in oncology, inflammation, and blood disorders Under the collaboration, Similis Bio will provide full processes and associated IP for tech transfer to Blau…
February 2, 2023

Read more

Load more